Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Wednesday, June 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Madrigal Pharmaceuticals, Inc. has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11, 2024. The presentation will take place at 8:40 A.M. ET and will be available via a live webcast. The company is known for its focus on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), particularly its drug Rezdiffra (resmetirom), which aims to address key issues related to this liver disease. A replay of the webcast will be accessible after the event, further providing opportunities for investor engagement.
Price reaction · baseline $244.35 (2024-06-04 close) · hit after-hours · 1 other MDGL headline(s) in the window, move may be shared
day 0 close
-3.4%
day 1
-1.2%
day 3
+4.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a high-profile healthcare conference increases visibility.
  • Live presentation and replay available, enhancing investor engagement.
  • Focus on NASH, a condition with significant unmet medical need, showcases potential impact.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Frequently Asked Questions

When will Madrigal Pharmaceuticals present at the conference?

Madrigal will present at 8:40 A.M. ET on June 11, 2024.

Where can I watch the Madrigal conference presentation?

The presentation will be webcast live on Madrigal's website.

What is Madrigal Pharmaceuticals focused on developing?

Madrigal is focused on therapies for nonalcoholic steatohepatitis (NASH).

What is Rezdiffra designed to treat?

Rezdiffra (resmetirom) is designed to target key causes of NASH.

How often is Rezdiffra taken?

Rezdiffra is a once-daily oral medication.

ShareAdd on Google
Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals Goldman Sachs healthcare NASH
Last updated: Jun 5, 2024

Biotech snapshot

Cash runway
$839M liquidity · $19M/mo burn
~45 mo
Minimal dilution risk
Lead asset
ResmetiromPhase 3
Non-Alcoholic Fatty Liver Disease →

Catalyst track record

+125%
best trade around MDGL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MDGL.

See every catalyst's timing & PoA →